Form 4: Artiva Biotherapeutics Executive Christopher Horan Receives 25,000 Restricted Stock Units

Christopher Horan, Chief Tech Operations Officer at Artiva Biotherapeutics, was granted 25,000 restricted stock units on September 12, 2024.

Summary

• On September 12, 2024, Christopher Horan, the Chief Tech Operations Officer of Artiva Biotherapeutics, Inc., received a grant of 25,000 shares of common stock in the form of restricted stock units.
• The restricted stock units were awarded under the Issuer's 2024 Equity Incentive Plan.
• Following this transaction, Mr. Horan beneficially owns 25,000 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively. It indicates that the company is incentivizing its key personnel.

Positives

• The grant of restricted stock units aligns Mr. Horan's interests with those of the shareholders.
• The 2024 Equity Incentive Plan is designed to attract, retain, and motivate key employees.

Industry Context

Equity grants are a common practice in the biotechnology industry to incentivize and retain key personnel. This grant is consistent with industry standards for executive compensation.

Comparison to Industry Standards

• Many biotechnology companies, such as Amgen, Gilead Sciences, and Biogen, utilize equity-based compensation plans to align executive interests with shareholder value.
• Restricted stock units are a standard component of these plans, offering executives a stake in the company's long-term success.
• The size of the grant is likely determined by factors such as the executive's role, performance, and the company's overall compensation strategy.

Stakeholder Impact

• Shareholders may view the equity grant as a positive sign, indicating that management's interests are aligned with theirs.
• Employees may be motivated by the fact that executives are being incentivized to improve company performance.

Key Dates